Syntis Bio is a technology company.
Syntis Bio has raised $33.0M across 1 funding round.
Syntis Bio has raised $33.0M in total across 1 funding round.
Syntis Bio is a clinical-stage biopharmaceutical company founded in 2022 and headquartered in Boston, Massachusetts, developing oral therapies that leverage proprietary SYNT™ technology—a synthetic tissue-lining polymer—to target the small intestine for metabolic control, digestion, and drug absorption[1][2][3][4]. The company serves patients with obesity, diabetes, and rare metabolic diseases like homocystinuria (HCU) and maple syrup urine disease (MSUD), addressing unmet needs through once-daily pills that mimic gastric bypass effects (e.g., lead program SYNT-101 blocks duodenal nutrient absorption) or deliver gut-restricted enzymes (e.g., SYNT-202 and SYNT-203)[1][2][3]. With preclinical data from over 100 pig studies showing 70% glucose blocking, 20x enzyme activity improvement, and 4-10x drug bioavailability gains, Syntis has raised $15.5 million and expanded via a 2024 Codexis acquisition, positioning it for IND filings in 2025 and Phase 1 obesity data in March 2026[1][2][3].
Syntis Bio emerged from MIT labs in 2022, co-founded by Robert Langer (biomaterials pioneer), Giovanni Traverso (GI physiology expert), and Rahul Dhanda (current President & CEO with biotech experience)[1][2][5][6]. The idea sparked from a Bill & Melinda Gates Foundation challenge to boost oral drug bioavailability for children in low-resource settings, leading to SYNT™—mussel-inspired polymer chemistry that coats GI tissues transiently for up to 24 hours[3][4][6]. Early traction included preclinical pig studies validating the platform's versatility, a stealth phase launch in 2024 with obesity and rare disease focus, and pipeline expansion through acquiring Codexis enzymes, setting the stage for human trials[1][5].
Syntis rides the explosive demand for oral GLP-1 alternatives and orphan metabolic therapies, capitalizing on small intestine biology as the "gut-brain axis" nexus amid rising obesity (affecting 1B+ globally) and rare disease gaps[1][4]. Timing aligns with post-GLP-1 innovation waves, where injectables dominate but patients seek sustainable pills; market forces like $100B+ obesity sector growth and FDA orphan incentives favor SYNT™'s non-invasive edge over surgery/enzymatics[2][3]. By enabling oral biologics and bioavailability leaps, Syntis influences biotech ecosystems, potentially accelerating GI-targeted platforms from MIT spinouts and drawing strategic investors[1][5][6].
Syntis is primed for inflection with 2025 IND filings for SYNT-202/203 and March 2026 Phase 1 obesity data, expanding into pancreatic insufficiency and ulcers amid oral therapy booms[1][2]. Trends like AI-driven enzyme design and GLP-1 fatigue will amplify SYNT™'s edge, evolving its influence from rare disease pioneer to metabolic blockbuster contender—unlocking the small intestine as biotech's next command center, much like its founders first envisioned for global access[3][4][6].
Syntis Bio has raised $33.0M in total across 1 funding round.
Syntis Bio's investors include Alumni Ventures, Bold Capital Partners, Digitalis Ventures, Justin Mateen.
Syntis Bio has raised $33.0M across 1 funding round. Most recently, it raised $33.0M Series A in June 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2025 | $33.0M Series A | Alumni Ventures, Bold Capital Partners, Digitalis Ventures, Justin Mateen |